Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of gadoPIClenol for CenTral NervoUs System (CNS) Magnetic REsonance Imaging (MRI)

Next Previous
Trial Profile

Efficacy and Safety of gadoPIClenol for CenTral NervoUs System (CNS) Magnetic REsonance Imaging (MRI)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gadopiclenol (Primary) ; Gadobutrol
  • Indications CNS disorders
  • Focus Diagnostic use
  • Acronyms PICTURE
  • Sponsors Guerbet

Most Recent Events

  • 25 Apr 2024 According to a Guerbet media release, the significant benefits of Elucirem (Gadopiclenol) in terms of efficacy and safety were reported in Phase III clinical study (PICTURE1) published in Investigative Radiology in 2023.
  • 11 Dec 2023 According to a Guerbet media release, Primary endpoint (Lesion visualization criteria based on 3 co-primary criteria: border delineation, internal morphology and degree of contrast enhancement, assessed on the images acquired during the MRI performed with gadopiclenol (criteria 1) and the MRI performed with gadopiclenol and those performed with gadobutrol (criteria 2) has been met.
  • 11 Dec 2023 According to a Guerbet media release, Primary endpoint (lesion visualization criteria for gadopiclenol-enhanced MRI compared to unenhanced MRI) has been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top